Medical illness and schizophrenia /

par Meyer, Jonathan M., Nasrallah, Henry A.
Publié 2003.

Moving Ahead with the Schizophrenia Concept: From the Elephant to the Mouse

par Keshavan, Matcheri S, Nasrallah, Henry A, Tandon, Rajiv
Publié 2011

NEW DRUG DEVELOPMENTS IN PSYCHOSIS: CHALLENGES, OPPORTUNITIES AND STRATEGIES

par Keshavan, Matcheri S., Lawler, Ashley N., Nasrallah, Henry A., Tandon, Rajiv
Publié dans Prog Neurobiol (2016)

Protection from olanzapine-induced metabolic toxicity in mice by acetaminophen and tetrahydroindenoindole

par Shertzer, Howard G., Kendig, Eric L., Nasrallah, Henry A., Johansson, Elisabet, Genter, Mary Beth
Publié 2010

Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies

par Nasrallah, Henry A., Cucchiaro, Josephine B., Mao, Yongcai, Pikalov, Andrei A., Loebel, Antony D.
Publié dans CNS Spectr (2014)

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study

par Durgam, Suresh, Landbloom, Ronald P, Mackle, Mary, Wu, Xiao, Mathews, Maju, Nasrallah, Henry A
Publié dans Neuropsychiatr Dis Treat (2017)

Metabolic and Endocrine Profiles During 1-Year Treatment of Outpatients with Schizophrenia with Aripiprazole Lauroxil

par Nasrallah, Henry A., Aquila, Ralph, Stanford, Arielle D., Jamal, Hasan H., Weiden, Peter J., Risinger, Robert
Publié dans Psychopharmacol Bull (2017)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

par Nasrallah, Henry A., Earley, Willie, Cutler, Andrew J., Wang, Yao, Lu, Kaifeng, Laszlovszky, István, Németh, György, Durgam, Suresh
Publié dans BMC Psychiatry (2017)

A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia

par Nasrallah, Henry A, Gopal, Srihari, Gassmann-Mayer, Cristiana, Quiroz, Jorge A, Lim, Pilar, Eerdekens, Mariëlle, Yuen, Eric, Hough, David
Publié 2010

Lipidomics Reveals Early Metabolic Changes in Subjects with Schizophrenia: Effects of Atypical Antipsychotics

par McEvoy, Joseph, Baillie, Rebecca A., Zhu, Hongjie, Buckley, Peter, Keshavan, Matcheri S., Nasrallah, Henry A., Dougherty, George G., Yao, Jeffrey K., Kaddurah-Daouk, Rima
Publié 2013

Measurement-based Care in Psychiatry—Past, Present, and Future

par Aboraya, Ahmed, Nasrallah, Henry A., Elswick, Daniel E., Ahmed, Elshazly, Estephan, Nevine, Aboraya, Dalia, Berzingi, Seher, Chumbers, Josleen, Berzingi, Sara, Justice, John, Zafar, Jawad, Dohar, Sheena
Publié dans Innov Clin Neurosci (2018)

Recent Advances in Understanding and Mitigating Adipogenic and Metabolic Effects of Antipsychotic Drugs

par Gohlke, Julia M., Dhurandhar, Emily J., Correll, Christoph U., Morrato, Elaine H., Newcomer, John W., Remington, Gary, Nasrallah, Henry A., Crystal, Stephen, Nicol, Ginger, Allison, David B.
Publié 2012

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: Results from a randomized co...

par Stroup, T. Scott, Byerly, Matthew J., Nasrallah, Henry A., Ray, Neepa, Khan, Ahsan Y., Lamberti, J. Steven, Glick, Ira D., Steinbook, Richard M., McEvoy, Joseph P., Hamer, Robert M.
Publié 2013

Inflammatory Markers in Schizophrenia: Comparing Antipsychotic Effects in Phase 1 of the CATIE Schizophrenia Trial

par Meyer, Jonathan M., McEvoy, Joseph P., Davis, Vicki G., Goff, Donald C., Nasrallah, Henry A., Davis, Sonia M., Hsiao, John K., Swartz, Marvin S., Stroup, T. Scott, Lieberman, Jeffrey A.
Publié 2009

Impact of Antipsychotic Treatment on Nonfasting Triglycerides in the CATIE Schizophrenia Trial Phase 1

par Meyer, Jonathan M., Davis, Vicki G., McEvoy, Joseph P., Goff, Donald C., Nasrallah, Henry A., Davis, Sonia M., Daumit, Gail L., Hsiao, John, Swartz, Marvin S., Stroup, T. Scott, Lieberman, Jeffrey A.
Publié 2008

Antipsychotic effects on estimated 10 year coronary heart disease risk in the CATIE Schizophrenia Study

par Daumit, Gail L., Goff, Donald C., Meyer, Jonathan M., Davis, Vicki G., Nasrallah, Henry A., McEvoy, Joseph P., Rosenheck, Robert, Davis, Sonia M., Hsiao, John K., Stroup, T. Scott, Lieberman, Jeffrey A.
Publié 2008

Change in Metabolic Syndrome Parameters With Antipsychotic Treatment in the CATIE Schizophrenia Trial: Prospective Data From Phase 1

par Meyer, Jonathan M., Davis, Vicki G., Goff, Donald C., McEvoy, Joseph P., Nasrallah, Henry A., Davis, Sonia M., Rosenheck, Robert A., Daumit, Gail L., Hsiao, John, Swartz, Marvin S., Stroup, T. Scott, Lieberman, Jeffrey A.
Publié 2008

Evaluation of HLA Polymorphisms in Relation to Schizophrenia Risk and Infectious Exposure

par Bamne, Mikhil, Wood, Joel, Chowdari, Kodavali, Watson, Annie M., Celik, Cemil, Mansour, Hader, Klei, Lambertus, Gur, Ruben C., Bradford, L. DiAnne, Calkins, Monica E., Santos, Alberto B., Edwards, Neil, Kwentus, Joseph, McEvoy, Joseph P., Allen, Trina B., Savage, Robert M., Nasrallah, Henry A., Gur, Raquel E., Perry, Rodney T., Go, Rodney C.P., Devlin, Bernie, Yolken, Robert, Nimgaonkar, Vishwajit L.
Publié 2012